418
0 Kommentare
Galapagos and AbbVie expand their cystic fibrosis collaboration - Seite 3
About Galapagos
Galapagos (Euronext & NASDAQ: GLPG) is a clinical-stage biotechnology company specialized in the discovery and development of
small molecule medicines with novel modes of action. Our pipeline comprises a maturing pipeline of Phase 2, Phase 1, pre-clinical, and discovery programs in cystic fibrosis, inflammation,
fibrosis, osteoarthritis and other indications. We have discovered and developed filgotinib: in collaboration with Gilead we aim to bring this JAK1-selective inhibitor for inflammatory
indications to patients all over the world. Galapagos is focused on the development and commercialization of novel medicines that will improve people's lives. The Galapagos group,
including fee-for-service subsidiary Fidelta, has approximately 440 employees, operating from its Mechelen, Belgium
headquarters and facilities in The Netherlands, France, and Croatia. More information at www.glpg.com.
Contacts
Investors: | Media: |
Elizabeth Goodwin | Evelyn Fox |
VP IR & Corporate Communications | Director Communications |
+1 781 460 1784 Paul van der Horst Director IR & Business Development +31 6 53 725 199 |
+31 6 53 591 999 communications@glpg.com |
ir@glpg.com |
Lesen Sie auch
Forward-looking statements
This release may contain forward-looking statements, including statements regarding any anticipated milestone payments or royalty payments, the anticipated timing of clinical
studies, the potential activity of its candidate cystic fibrosis drugs and of a potential triple combination including these compounds for cystic
fibrosis. Galapagos cautions the reader that forward-looking statements are not guarantees of future performance. Forward-looking statements involve known and unknown risks,
uncertainties and other factors which might cause the actual results, financial condition and liquidity, performance or achievements of Galapagos, or industry results, to be materially different
from any historic or future results, financial conditions and liquidity, performance or achievements expressed or implied by such forward-looking statements. In addition, even if Galapagos'
results, performance, financial condition and liquidity, and the development of the industry in which it operates are consistent with such forward-looking statements, they may not be predictive of
results or developments in future periods. Among the factors that may result in differences are the inherent uncertainties associated with competitive developments, clinical trial and product
development activities and regulatory approval requirements (including that data from Galapagos' ongoing clinical research programs in cystic fibrosis may not support registration or further
development of their correctors and potentiators due to safety, efficacy or other reasons), Galapagos' reliance on collaborations with third parties (including the performance by AbbVie under the
Galapagos-AbbVie Collaboration Agreement), and estimating the commercial potential of its product candidates. A further list and description of these risks, uncertainties and other risks can
be found in Galapagos' Securities and Exchange Commission (SEC) filings and reports, including in Galapagos' most recent annual report on Form 20-F filed with the SEC and subsequent filings and
reports filed by Galapagos with the SEC. Given these uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements. These forward-looking
statements speak only as of the date of publication of this document. Galapagos expressly disclaims any obligation to update any such forward-looking statements in this document to reflect
any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based or that may affect the likelihood that actual results
will differ from those set forth in the forward-looking statements, unless specifically required by law or regulation.